FDA Clears NexSys PCS Plasma System With Persona PLUS
BOSTON, Feb. 23, 2026 — Haemonetics Corporation announced that the U.S. Food and Drug Administration granted 510(k) clearance for...
AI drug discovery Alzheimer’s Disease artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biotechnology Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology oncology innovation Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory compliance targeted therapy
BOSTON, Feb. 23, 2026 — Haemonetics Corporation announced that the U.S. Food and Drug Administration granted 510(k) clearance for...
SAN JOSE, Calif., Feb. 23, 2026 — Anixa Biosciences announced that immunology leader Jose Conejo-Garcia, M.D., Ph.D., will keynote...
SAN DIEGO, Calif. & CAMBRIDGE, Mass., Feb. 9, 2026 — Clinical-stage life science technology company Iambic Therapeutics has entered...
SAN JOSE, Calif., Feb. 9, 2026 — Anixa Biosciences reported encouraging survival observations from its ongoing Phase 1 ovarian...
